TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23125943

Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg/24 hours)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gauze dressing daily for 7 days
Number of subjects: 41
Study: 20021250

Group type: EXPERIMENTAL
Intervention: Topical bevacizumab (5 mg/ml) twice a day and betamethasone four times daily for 1 week
Number of subjects: 54

Group type: COMPARATOR
Intervention: Betamethasone alone four times daily for 1 week
Number of subjects: 54
Study: 17088311

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16048482

Group type: EXPERIMENTAL
Intervention: Helixone membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AN69ST membrane
Number of subjects: 10
Study: 12145073

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 44
Study: 8907343

Group type: EXPERIMENTAL
Intervention: Allopurinol (10 mg/kg/day during the first week and 15 mg/kg/day thereafter)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 17
Study: 2181755

Group type: EXPERIMENTAL
Intervention: Oral terbutaline 7.5 mg twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 395522

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31838585

Group type: EXPERIMENTAL
Intervention: HER2 positivity assessment in gallbladder carcinoma
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Dual HER2 inhibition treatment
Number of subjects: 186

Group type: COMPARATOR
Intervention: HER2 status comparison between positive and negative groups
Number of subjects: 186
Study: 31163062

Group type: EXPERIMENTAL
Intervention: Positive mood induction (video clips followed by music excerpts with Velten statements)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Negative mood induction (video clips followed by music excerpts with Velten statements)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Velten statements (self-referential)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Closed eyes instructions
Number of subjects: 551

Group type: COMPARATOR
Intervention: Neutral Velten statements (factual)
Number of subjects: 551
Study: 27111441

Group type: EXPERIMENTAL
Intervention: PT+coaching (physiotherapy and coaching group)
Number of subjects: 168

Group type: COMPARATOR
Intervention: PT-only (physiotherapy-only group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: PT+coaching
Number of subjects: 168

Group type: COMPARATOR
Intervention: PT-only
Number of subjects: 168
Study: 28407999

Group type: EXPERIMENTAL
Intervention: Spacing strategy (TNF-blocker injection spacing)
Number of subjects: 98
Study: 23376451

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg tid) plus Behavioral Weight Loss (BWL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo plus Behavioral Weight Loss (BWL)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Orlistat plus BWL
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: BWL
Number of subjects: 79
Study: 21454244

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to the abdomen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to the upper arms/shoulders
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel alternating between abdomen and upper arms/shoulders
Number of subjects: 36
Study: 19703642

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 7
Study: 17726409

Group type: EXPERIMENTAL
Intervention: Single-dose intramuscular dexamethasone (0.6 mg/kg, maximum 15 mg)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg, maximum 50 mg)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Single-dose intramuscular dexamethasone
Number of subjects: 181

Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 181
Study: 15210738

Group type: EXPERIMENTAL
Intervention: 30 Gy involved-field radiotherapy (RT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 30 Gy involved-field RT
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 40 Gy RT
Number of subjects: 172
Study: 11878525

Group type: EXPERIMENTAL
Intervention: Sitting for 20 minutes after administration of 3 ml of 0.5% hyperbaric bupivacaine solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sitting for 2, 5, or 10 minutes after administration of 3 ml of 0.5% hyperbaric bupivacaine solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (2, 5, 10, and 20 minutes sitting)
Number of subjects: 60
Study: 10450749

Group type: EXPERIMENTAL
Intervention: GM-CSF, 5 microg/kg/day from day 4 to day 8 of EMA chemotherapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo from day 4 to day 8 of EMA chemotherapy
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 8696574

Group type: EXPERIMENTAL
Intervention: Durapore silk tape
Number of subjects: 2

Group type: COMPARATOR
Intervention: Medipore soft cloth tape
Number of subjects: 2
Study: 2618792

Group type: EXPERIMENTAL
Intervention: Counting seconds (either mentally or aloud)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No counting of seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constant force conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variable force conditions ('Slow' and 'Rapid')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both counting and no counting groups
Number of subjects: 0
Study: 793849

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 20
Study: 31263283

Group type: EXPERIMENTAL
Intervention: Transplantation of human fetal ventral mesencephalic tissue (hfVM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Observational cohort assessments
Number of subjects: 11
Study: 28068788

Group type: EXPERIMENTAL
Intervention: Probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 79
Study: 25555154

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 12 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (matched by age and sex)
Number of subjects: 44
Study: 23332688

Group type: EXPERIMENTAL
Intervention: Microfibrillar collagen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxidized cellulose
Number of subjects: 0
Study: 21132493

Group type: EXPERIMENTAL
Intervention: Haptic condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between haptic and visual deviations
Number of subjects: 0
Study: 19474657

Group type: COMPARATOR
Intervention: LAC group: lansoprazole 30 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 14 days
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: BLTM group: bismuth subcitrate 300 mg 4 times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: RBLTM group: ranitidine bismuth citrate 400 mg twice daily, lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: LTM group: lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Number of subjects: 464
Study: 16499488

Group type: EXPERIMENTAL
Intervention: Gelatin 'shots'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol beverage
Number of subjects: 0
Study: 15571316

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily for 14 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Loratadine 10 mg once daily for 14 days
Number of subjects: 67
Study: 11510874

Group type: EXPERIMENTAL
Intervention: Heat-induced dehydration after coffee consumption (caffeine 4.9 mg/kg, 3-4 cups)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (same amount of coffee, remained euhydrated)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heat-induced dehydration after coffee consumption
Number of subjects: 10
Study: 9226080

Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety Depression Scale (depression subscale)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Zung Self‐Rating Depression Scale
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Profile of Mood States (depression subscale)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Three instruments combined
Number of subjects: 200
Study: 8543958

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595

Group type: EXPERIMENTAL
Intervention: Computerised linkage reporting
Number of subjects: 6595

Group type: COMPARATOR
Intervention: Traditional patient follow-up methods
Number of subjects: 6595
Study: 2472488

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon-beta serine (IFN‐beta ser)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous interferon-beta serine (IFN‐beta ser)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Higher dose of interferon-beta serine (180 X 10(6) IU)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lower dose of interferon-beta serine (45 X 10(6) IU)
Number of subjects: 16
Study: 30579569

Group type: EXPERIMENTAL
Intervention: BIKEN varicella-zoster vaccine (BVZV) with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Number of subjects: 52
Study: 28514964

Group type: EXPERIMENTAL
Intervention: Hospital Elder Life Program (HELP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study: 26602296

Group type: EXPERIMENTAL
Intervention: WASH intervention (protecting babies from fecal ingestion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IYCF intervention (optimizing nutritional adequacy of infant diet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined WASH and IYCF interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers of intestinal structure and function, microbial translocation, systemic inflammation, and hormonal determinants of growth and anemia
Number of subjects: 0
Study: 24199742

Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study: 21823420

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Recipe (BSHXR), one dose per day (taken in two times) for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Monopril 10 mg, once daily for 8 weeks (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Recipe (BSHXR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Monopril 10 mg, once daily (control group)
Number of subjects: 45
Study: 18465239

Group type: EXPERIMENTAL
Intervention: Renzapride (1, 2, or 4 mg/day)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 16835029

Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 15018590

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIg) therapy
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 100000
Study: 11168085

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir therapy
Number of subjects: 14
Study: 9049557

Group type: EXPERIMENTAL
Intervention: IVRA with prilocaine and clonidine 2 micrograms kg‐1
Number of subjects: 56

Group type: COMPARATOR
Intervention: IVRA with prilocaine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: IVRA with prilocaine and systemic application of clonidine at tourniquet release
Number of subjects: 56
Study: 8325047

Group type: EXPERIMENTAL
Intervention: Sulodexide 250 LRU (= 25 mg) capsules twice daily
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Sulodexide 50 mg enteric-coated tablets twice daily
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Sulodexide 100 mg enteric-coated tablets once daily
Number of subjects: 476

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 476
Study: 3630465

Group type: EXPERIMENTAL
Intervention: Bed rest with additional daily administered glucose infusions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bed rest with additional oral galactose applications
Number of subjects: 45

Group type: COMPARATOR
Intervention: Strict bed rest alone
Number of subjects: 45
Study: 30238060

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling plus quarterly clinical examinations, fluoride varnish applications, toothbrush/toothpaste, and educational brochures
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Quarterly clinical examinations, fluoride varnish applications, toothbrush/toothpaste, and educational brochures
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling plus intensive caries prevention activities
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1065
Study: 27379995

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) group, 208 patients
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual-care group, 91 patients
Number of subjects: 299
Study: 25174986

Group type: EXPERIMENTAL
Intervention: Home-based pedometer walking programme
Number of subjects: 42
Study: 23801357

Group type: COMPARATOR
Intervention: Ponatinib 15 mg alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg with ketoconazole 400 mg daily for 5 days
Number of subjects: 22
Study: 21166853

Group type: EXPERIMENTAL
Intervention: Insulin group (n=144, 70% of insulin users)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Insulin group (n=144)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Overall population (n=1047)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Overall population with cognitive impairment (n=235)
Number of subjects: 1047
Study: 18305883

Group type: EXPERIMENTAL
Intervention: Processing speed at baseline
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Baseline neurocognitive performance
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 708
Study: 16567674

Group type: EXPERIMENTAL
Intervention: LifeSite hemodialysis access system
Number of subjects: 68

Group type: COMPARATOR
Intervention: Tesio-Cath hemodialysis catheter
Number of subjects: 68
Study: 12659614

Group type: EXPERIMENTAL
Intervention: Various potential treatments for FSD, specific interventions not detailed.
Number of subjects: 0
Study: 10917987

Group type: EXPERIMENTAL
Intervention: Reversed saphenous vein
Number of subjects: 136

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene
Number of subjects: 136
Study: 8725734

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1548516

Group type: EXPERIMENTAL
Intervention: Carboplatin (40 to 1,000 mg/m2)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Number of subjects: 1028
Study: 6510389

Group type: EXPERIMENTAL
Intervention: Breathing 50 ppm carbon monoxide (CO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Breathing purified air
Number of subjects: 10
Study: 31544802

Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR) for 9±2 months with weight gain >7g/d
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nutritional rehabilitation (NR) for 9±2 months with weight gain <7g/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group A (28 children who improved their BMI‐SDS after NR)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group B (23 children who did not improve their BMI‐SDS after NR)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR)
Number of subjects: 102
Study: 28052451

Group type: EXPERIMENTAL
Intervention: Nadroparin infusion (loading dose of 35 IU/kg and continuous infusion of 10 IU/kg per hour for 6 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 12
Study: 26314877

Group type: EXPERIMENTAL
Intervention: Patient Competency Rating Scale (task-by-task approach)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Patient Competency Rating Scale (functional domains approach)
Number of subjects: 83
Study: 24840596

Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structured Applied Behavior Analysis (ABA)
Number of subjects: 0
Study: 22525397

Group type: EXPERIMENTAL
Intervention: Advance Organizers (AO)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pretests (PT)
Number of subjects: 65
Study: 20497139

Group type: EXPERIMENTAL
Intervention: PN 400 (enteric-coated naproxen 500 mg and immediate-release esomeprazole 20 mg)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: PN 400
Number of subjects: 864

Group type: COMPARATOR
Intervention: EC naproxen
Number of subjects: 864
Study: 17605967

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic stenosis of more than 70%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic stenosis of more than 50%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stenting for carotid stenosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endarterectomy vs stenting
Number of subjects: 0
Study: 16117455

Group type: EXPERIMENTAL
Intervention: Group I (3 degrees C difference)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group II (5 degrees C difference)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group III (7 degrees C difference)
Number of subjects: 30
Study: 12356214

Group type: EXPERIMENTAL
Intervention: Single-agent mitoxantrone (MITO) therapy
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Published reports of nine additional studies of single-agent MITO therapy for MS
Number of subjects: 1378
Study: 10028979

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularisation (TMLR)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 188
Study: 7745043

Group type: EXPERIMENTAL
Intervention: Co-culture with human skin fibroblast monolayers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal semen analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal semen analysis
Number of subjects: 0
Study: 2387277

Group type: COMPARATOR
Intervention: Soy sauce added to soy flour meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy sauce added to rice meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy sauce added to rice meal alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactic acid added to rice
Number of subjects: 0
Study: 7148735

Group type: EXPERIMENTAL
Intervention: Aspartame plus monosodium L-glutamate (34 mg/kg body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control meal (no additions)
Number of subjects: 6
Study: 31694107

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) with Gemcitabine+Cisplatin three weeks regimen
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 176
Study: 28248887

Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil 1.0 μg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil 1.5 μg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil 2.0 μg/kg
Number of subjects: 3
Study: 26546068

Group type: EXPERIMENTAL
Intervention: Exercise (aerobic and strength training 3-4 days/week at 60% HRres, 50% RM for moderate intensity; 80% HRres, 70% RM for vigorous intensity)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 150
Study: 24153171

Group type: EXPERIMENTAL
Intervention: Surgery (open discectomy)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 1244
Study: 20883985

Group type: EXPERIMENTAL
Intervention: Metformin treatment for 4 years
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 38
Study: 18726908

Group type: EXPERIMENTAL
Intervention: Pramipexole (D2/D3 agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17522474

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Kidney/Ureter/Bladder X-ray (KUB)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of US+CT+KUB
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of US+CT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of KUB+CT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Two exams suggesting NC diagnosis (including CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Evaluation of exams together
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: First and second reviews by observers
Number of subjects: 62
Study: 16213310

Group type: EXPERIMENTAL
Intervention: Taguchi technique
Number of subjects: 144

Group type: COMPARATOR
Intervention: Modified Lich-Gregoir technique
Number of subjects: 144
Study: 12322866

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic therapy
Number of subjects: 45